Literature DB >> 27390367

Improved walking speed is associated with lower hospitalisation rates in patients in an exercise-based secondary prevention programme.

Giovanni Grazzi1,2, Gianni Mazzoni1,2, Jonathan Myers3,4, Luciano Codecà2,5, Giovanni Pasanisi6, Nicola Napoli7, Franco Guerzoni7, Stefano Volpato8, Francesco Conconi2, Giorgio Chiaranda9.   

Abstract

OBJECTIVE: To determine the relationship between walking speed (WS) maintained during a 1 km test and its improvement on hospitalisation in cardiac outpatients who were referred to an exercise-based secondary prevention programme.
METHODS: Hospitalisation was assessed in 1791 patients 3 years after enrolment and related to the WS achieved during a 1 km walk at moderate intensity on a treadmill. Hospitalisation was also assessed during the fourth-to-sixth years as function of improvement in WS in 1111 participants who were re-evaluated 3 years after baseline.
RESULTS: Three-year hospitalisation rate across tertiles of baseline WS was 50% for the slow walkers (2.7±0.6 km/hour), 41% for the moderate (4.1±0.3 km/hour) and 25% for the fast walkers (5.2±0.5 km/hour) (p for trend <0.0001), with adjusted HRs (95% CI) of 0.93 (0.74 to 1.17, p=0.53) for intermediate and 0.58 (0.43 to 0.78, p=0.0003) for fast. Every 1 km/hour increase in WS was associated with a 21% reduction in hospitalisation (p<0.0001). Hospitalisation from the fourth-to-sixth years was lower across tertiles of improved WS, with 44% for the low (0.2±0.4 km/hour), 34% for the intermediate (0.8±0.2 km/hour) and 30% for the high tertile (1.6±0.4 km/hour) (p for trend <0.0001). Adjusted HRs were 0.68 (p=0.002) for the intermediate and 0.58 (p<0.0001) for the high tertile. Every 1 km/hour increase in WS was associated with a 35% reduction in hospitalisation (p<0.0001).
CONCLUSION: Improvement in WS is associated with a significant, dose-dependent lower rate of all-cause hospitalisation in cardiac outpatients. WS is a simple, easily applied and clinically useful tool for cardiac patients undergoing secondary prevention. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Mesh:

Year:  2016        PMID: 27390367     DOI: 10.1136/heartjnl-2015-309126

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  L-Arginine Enhances the Effects of Cardiac Rehabilitation on Physical Performance: New Insights for Managing Cardiovascular Patients During the COVID-19 Pandemic.

Authors:  Pasquale Mone; Raffaele Izzo; Giuseppe Marazzi; Maria Virginia Manzi; Paola Gallo; Giuseppe Campolongo; Luca Cacciotti; Domenico Tartaglia; Giuseppe Caminiti; Fahimeh Varzideh; Gaetano Santulli; Valentina Trimarco
Journal:  J Pharmacol Exp Ther       Date:  2022-03-26       Impact factor: 4.402

2.  The utility of personal activity trackers (Fitbit Charge 2) on exercise capacity in patients post acute coronary syndrome [UP-STEP ACS Trial]: a randomised controlled trial protocol.

Authors:  Jason Nogic; Paul Min Thein; James Cameron; Sam Mirzaee; Abdul Ihdayhid; Arthur Nasis
Journal:  BMC Cardiovasc Disord       Date:  2017-12-29       Impact factor: 2.298

3.  Effectiveness and safety of a home-based cardiac rehabilitation programme of mixed surveillance in patients with ischemic heart disease at moderate cardiovascular risk: A randomised, controlled clinical trial.

Authors:  Raquel Bravo-Escobar; Alicia González-Represas; Adela María Gómez-González; Angel Montiel-Trujillo; Rafael Aguilar-Jimenez; Rosa Carrasco-Ruíz; Pablo Salinas-Sánchez
Journal:  BMC Cardiovasc Disord       Date:  2017-02-20       Impact factor: 2.298

Review 4.  A Review of Interventions to Improve Enrolment and Adherence to Cardiac Rehabilitation Among Patients Aged 65 Years or Above.

Authors:  Bashir M Matata; Sean Andrew Williamson
Journal:  Curr Cardiol Rev       Date:  2017

5.  A moderate 500-m treadmill walk for estimating peak oxygen uptake in men with NYHA class I-II heart failure and reduced left ventricular ejection fraction.

Authors:  Gianni Mazzoni; Biagio Sassone; Giovanni Pasanisi; Jonathan Myers; Simona Mandini; Stefano Volpato; Francesco Conconi; Giorgio Chiaranda; Giovanni Grazzi
Journal:  BMC Cardiovasc Disord       Date:  2018-04-16       Impact factor: 2.298

6.  Physical activity intervention for elderly patients with reduced physical performance after acute coronary syndrome (HULK study): rationale and design of a randomized clinical trial.

Authors:  Elisabetta Tonet; Elisa Maietti; Giorgio Chiaranda; Francesco Vitali; Matteo Serenelli; Giulia Bugani; Gianni Mazzoni; Rossella Ruggiero; Jonathan Myers; Giovanni Quinto Villani; Ursula Corvi; Giovanni Pasanisi; Simone Biscaglia; Rita Pavasini; Giulia Ricci Lucchi; Gianluigi Sella; Roberto Ferrari; Stefano Volpato; Gianluca Campo; Giovanni Grazzi
Journal:  BMC Cardiovasc Disord       Date:  2018-05-21       Impact factor: 2.298

7.  Tailored nurse-led cardiac rehabilitation after myocardial infarction results in better risk factor control at one year compared to traditional care: a retrospective observational study.

Authors:  Halldora Ögmundsdottir Michelsen; Marie Nilsson; Fredrik Scherstén; Ingela Sjölin; Alexandru Schiopu; Margret Leosdottir
Journal:  BMC Cardiovasc Disord       Date:  2018-08-15       Impact factor: 2.298

8.  Gait Speed and 1-Year Mortality Following Cardiac Surgery: A Landmark Analysis From the Society of Thoracic Surgeons Adult Cardiac Surgery Database.

Authors:  Jonathan Afilalo; Abhinav Sharma; Shuaiqi Zhang; J Matthew Brennan; Fred H Edwards; Michael J Mack; James B McClurken; Joseph C Cleveland; Peter K Smith; David M Shahian; Eric D Peterson; Karen P Alexander
Journal:  J Am Heart Assoc       Date:  2018-12-04       Impact factor: 5.501

9.  Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator.

Authors:  Ashley E Burch; Benjamin D'Souza; J Rod Gimbel; Ursula Rohrer; Tsuyoshi Masuda; Samuel Sears; Daniel Scherr
Journal:  Clin Cardiol       Date:  2019-11-11       Impact factor: 2.882

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.